Bacterial Infections  >>  Shanchol (oral cholera vaccine)  >>  Phase 4
Welcome,         Profile    Billing    Logout  

4 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Shanchol (oral cholera vaccine) / Sanofi
NCT00760825: A Study to Evaluate Safety and Immunogenicity of the Bivalent Killed Whole Cell Oral Cholera Vaccine in Adults and Children

Completed
4
200
RoW
killed bivalent (O1 and O139)whole cell oral cholera vaccine, Shanchol™
International Vaccine Institute, Shantha Biotechnics Limited, Christian Medical College, Vellore, India
Vibrio Cholerae
04/13
08/13
NCT01579448: Evaluation of a Boosting Regimen With Oral Cholera Vaccine

Completed
4
426
RoW
Shanchol™, oral cholera vaccine, Shanchol™, killed, whole cell, bivalent, oral cholera vaccine, no intervention
Sachin Desai, National Institute of Cholera and Enteric Diseases, India, Indian Council of Medical Research
Cholera
07/13
07/13
NCT01524640: Bridging Study for Killed Oral Cholera Vaccine in Ethiopia

Completed
4
216
RoW
Killed Bivalent (O1 and O139) whole cell oral cholera vaccine, Shanchol TM, Placebo, Non biologic placebo
International Vaccine Institute, Armauer Hansen Research Institute, Ethiopia, Ministry of Health, Ethiopia, Shantha Biotechnics Limited
Vibrio Cholerae, Cholera
08/13
08/13
NCT01949675: A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines

Completed
4
336
RoW
Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell, Shanchol™
Sanofi Pasteur, a Sanofi Company
Cholera
02/15
08/15

Download Options